Woodline Partners LP Sells 321,885 Shares of Biohaven Ltd. (NYSE:BHVN)

Woodline Partners LP lowered its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 34.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 601,922 shares of the company's stock after selling 321,885 shares during the period. Woodline Partners LP owned about 0.60% of Biohaven worth $22,482,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in BHVN. JPMorgan Chase & Co. boosted its holdings in shares of Biohaven by 144.5% during the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock worth $73,922,000 after purchasing an additional 1,169,721 shares during the period. Norges Bank purchased a new stake in Biohaven in the 4th quarter worth approximately $33,711,000. Farallon Capital Management LLC grew its position in shares of Biohaven by 21.6% in the 4th quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company's stock worth $165,392,000 after buying an additional 785,578 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Biohaven by 12.1% during the fourth quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company's stock valued at $260,735,000 after buying an additional 756,032 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Biohaven by 8.1% during the fourth quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock valued at $314,267,000 after buying an additional 628,211 shares during the period. Institutional investors own 88.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. William Blair upgraded shares of Biohaven to a "strong-buy" rating in a report on Thursday, April 24th. Robert W. Baird cut their target price on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a research note on Monday, April 28th. Royal Bank of Canada cut shares of Biohaven from an "outperform" rating to a "sector perform" rating and reduced their price target for the company from $54.00 to $21.00 in a research report on Monday. HC Wainwright restated a "buy" rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Finally, Cantor Fitzgerald raised Biohaven to a "strong-buy" rating in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Biohaven currently has a consensus rating of "Buy" and a consensus target price of $59.46.

Insider Buying and Selling at Biohaven

In other news, Director John W. Childs purchased 32,700 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This represents a 1.43% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 16.00% of the stock is owned by company insiders.

Biohaven Stock Up 3.0%

BHVN stock opened at $16.22 on Wednesday. The business has a 50 day moving average of $21.79 and a 200 day moving average of $33.72. The firm has a market cap of $1.66 billion, a PE ratio of -1.73 and a beta of 1.18. Biohaven Ltd. has a twelve month low of $14.69 and a twelve month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.50). On average, research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd. (NYSE:BHVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.